Ex Vivo-activated Autologous Lymph Node Lymphocytes

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameEx Vivo-activated Autologous Lymph Node Lymphocytes
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapyCell and gene therapy > Cell therapy > Source of cells > Lymph node-derived
Mechanisms of ActionUpdating
TargetsNot applicable
Therapy Area/IndicationsRichter's SyndromeFatigueWeight Loss +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer CenterNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsRichter's SyndromeFatigueWeight Loss +[13] 

Other Information

ATC CodeN/A
Related LinksN/A